System and method of analysis of protein using liquid chromatography-mass spectrometry
By modifying the desolvation gas with acid/base vapor, the method addresses ion suppression in LC-MS analysis, enhancing sensitivity and sequence coverage in protein characterization.
Patent Information
- Application Number
- JP2024153804
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-12
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing LC-MS-based protein characterization methods face challenges with data quality issues, particularly due to ion suppression effects from trifluoroacetic acid (TFA) in peptide mapping analysis, leading to reduced MS sensitivity and decreased sequence coverage.
A method involving the modification of desolvation gas with acid/base vapor and isopropanol is introduced to counter ion suppression during LC-MS analysis, enhancing MS sensitivity and improving peptide retention.
The method significantly enhances MS sensitivity by 4.9- to 5.8-fold, improving peptide mapping analysis and spectral quality, particularly for low abundance attributes in protein biologics, and maintaining improved sensitivity over extended periods.
Smart Images

Figure 2024166268000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates generally to methods and systems for protein characterization. [Background technology]
[0002] Electrospray ionization (ESI) mass spectrometry (MS) coupled with chromatographic and electrophoretic separation techniques is a key technique in proteomics. It has become an important tool for the detailed characterization of protein biologics in the analytical laboratory to support their development and regulatory submissions. As protein biologics must meet very high purity specifications, it is important to monitor and characterize proteins during the various stages of drug development and production.
[0003] Liquid chromatography-mass spectrometry (LC-MS)-based analysis of protein biopharmaceuticals would benefit greatly from improved data quality, which could subsequently lead to improved drug characterization with greater confidence and less ambiguity. A wide variety of LC-MS-based assays can be performed to characterize various protein attributes, among which peptide mapping analysis and intact mass analysis are the most routinely and widely applied. To improve analytical reliability and reduce ambiguity associated with data interpretation, continuous efforts must be made to improve data quality from LC-MS analysis, including using optimized experimental procedures, fine-tuned instrument parameters, and more advanced mass spectrometers.
[0004] From the above, it will be appreciated that there is a need for improved methods and systems for improving protein characterization. Summary of the Invention
[0005] Advances in the development, manufacture and sale of protein-based biopharmaceutical products have created an increasing demand for methods and systems for protein characterization.
[0006] SUMMARY OF THE DISCLOSURE The embodiments disclosed herein fulfill the above-mentioned needs by providing methods and systems for protein characterization.
[0007] The disclosure provides, at least in part, a method for characterizing proteins in a sample, comprising providing a sample to an inlet of an electrospray ionization source having, for example, a vessel having a cap with inlet and outlet line ports, a sheath gas inlet line, a modified desolvation gas outlet line, and an electrospray ionization probe having a sheath gas inlet, generating ions of protein constituents in the sample at the outlet of the electrospray ionization source, and analyzing the ions using a mass spectrometer to identify the protein constituents and characterize the protein.
[0008] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source equipped with a vessel having a cap with an inlet line port and an outlet line port, and a sheath gas inlet line capable of providing a sheath gas to the inlet line port.
[0009] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source with a vessel having a cap with an inlet line port and an outlet line port, and a modified desolvation gas outlet line capable of connecting the outlet line port to a sheath gas inlet of an electrospray ionization probe.
[0010] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source with a container surrounded by a second container.
[0011] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source with an electrospray ionization probe in a positive polarity mode.
[0012] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source with an electrospray ionization probe in a negative polarity mode.
[0013] In some exemplary embodiments, the method for characterizing proteins in a sample can include performing intact mass analysis.
[0014] In some exemplary embodiments, the method of characterizing proteins in a sample can include performing a peptide mapping analysis.
[0015] In some exemplary embodiments, the method of characterizing a protein in a sample can include characterizing an antibody.
[0016] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a reservoir containing an organic solvent.
[0017] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a reservoir containing an organic solvent and an acid.
[0018] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a reservoir containing an organic solvent and a base.
[0019] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a container containing acetonitrile.
[0020] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a reservoir containing triethylamine (TEA).
[0021] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a reservoir containing trifluroacetic acid.
[0022] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe with an auxiliary gas inlet.
[0023] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe with an electrospray emitter needle.
[0024] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source equipped with a vessel having a cap with an inlet line port and an outlet line port, and a sheath gas inlet line capable of providing nitrogen gas to the inlet line port.
[0025] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe with an auxiliary gas inlet, which can be capable of supplying an auxiliary gas.
[0026] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe with an auxiliary gas inlet, which can be supplied with nitrogen gas.
[0027] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow line, and an auxiliary gas flow line.
[0028] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing, and the electrospray ionization probe can be configured to direct flow in the sheath gas flow tubing coaxially with respect to the electrospray emitter needle.
[0029] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing, and the electrospray ionization probe can be configured to direct flow in the auxiliary gas flow tubing coaxially with respect to the electrospray emitter needle.
[0030] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having an electrospray ionization probe, which can be a heated electrospray ionization probe.
[0031] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a cap with an inlet line port and a sheath gas inlet line, the sheath gas inlet line can be partially inserted into the inlet line port.
[0032] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a cap with an outlet line port and a modified desolvation gas outlet line, which can be partially inserted into the outlet line port.
[0033] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, wherein the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel and into the desolvation gas outlet line.
[0034] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, wherein the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel containing the organic solvent and into the desolvation gas outlet line.
[0035] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, where the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel containing the organic solvent and additional chemical constituents and into the desolvation gas outlet line.
[0036] In some exemplary embodiments, the method for characterizing proteins in a sample can include an electrospray ionization source capable of providing an electrospray with a solvent flow rate of greater than about 5 μL / min.
[0037] In some exemplary embodiments, a method for characterizing proteins in a sample can include an electrospray ionization source having a vessel, which can be a pressure-resistant vessel.
[0038] In some exemplary embodiments, the method for characterizing proteins in a sample can include an electrospray ionization source that can be interfaced to a liquid chromatography system.
[0039] In some exemplary embodiments, the method of characterizing a protein in a sample can include characterizing a digestion product of the protein.
[0040] In some exemplary embodiments, the method of characterizing a protein in a sample can include analyzing ions using a mass spectrometer to identify protein components and characterize the protein, and the mass spectrometer can be a tandem mass spectrometer.
[0041] This disclosure provides, at least in part, a liquid chromatography mass spectrometry system including a liquid chromatography apparatus, a vessel having a cap with an inlet line port and an outlet line port, an electrospray ionization source having a sheath gas inlet line, a modified desolvation gas outlet line, and an electrospray ionization probe, and a mass analyzer.
[0042] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source with a vessel having a cap with an inlet line port and an outlet line port, and a sheath gas inlet line capable of providing a sheath gas to the inlet line port.
[0043] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source with a vessel having a cap with an inlet line port and an outlet line port, and a modified desolvation gas outlet line that can connect the outlet line port to a sheath gas inlet of an electrospray ionization probe.
[0044] In some exemplary embodiments, the liquid chromatography mass spectrometry system can include an electrospray ionization probe, which can be operated in a positive polarity mode.
[0045] In some exemplary embodiments, the liquid chromatography mass spectrometry system can include an electrospray ionization probe, which can be operated in a negative polarity mode.
[0046] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a reservoir that can be filled with an organic solvent.
[0047] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a reservoir that can be filled with an organic solvent and an additional chemical component, which can include an acid, a base, a salt, or a combination thereof.
[0048] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a reservoir that can be filled with an organic solvent and an acid.
[0049] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a reservoir that can be filled with an organic solvent and a base.
[0050] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe with an auxiliary gas inlet.
[0051] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe with an electrospray emitter needle.
[0052] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source with a vessel having a cap with an inlet line port and an outlet line port, and a sheath gas inlet line capable of providing nitrogen gas to the inlet line port.
[0053] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe with an auxiliary gas inlet, which can be supplied with an auxiliary gas.
[0054] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe with an auxiliary gas inlet, which can be supplied with nitrogen gas.
[0055] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe that includes an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing.
[0056] In some exemplary embodiments, a liquid chromatography-mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing, and the electrospray ionization probe can be configured to direct flow in the sheath gas flow tubing coaxially with respect to the electrospray emitter needle.
[0057] In some exemplary embodiments, a liquid chromatography-mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing, and the electrospray ionization probe can be configured to direct flow in the auxiliary gas flow tubing coaxially with respect to the electrospray emitter needle.
[0058] In some exemplary embodiments, the liquid chromatography mass spectrometry system can include an electrospray ionization source having an electrospray ionization probe, which can be a heated electrospray ionization probe.
[0059] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a cap with an inlet line port and a sheath gas inlet line, which can be partially inserted into the inlet line port.
[0060] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a cap with an outlet line port and a modified desolvation gas outlet line, which can be partially inserted into the outlet line port.
[0061] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, and the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel and into the desolvation gas outlet line.
[0062] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, and the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel containing the organic solvent and into the desolvation gas outlet line.
[0063] In some exemplary embodiments, a liquid chromatography-mass spectrometry system can include an electrospray ionization source having a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, and the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel containing the organic solvent and additional components and into the desolvation gas outlet line.
[0064] In some exemplary embodiments, the liquid chromatography mass spectrometry system can include an electrospray ionization source capable of providing an electrospray solvent flow rate of greater than about 5 μL / min.
[0065] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a vessel surrounded by a second vessel.
[0066] In some exemplary embodiments, a liquid chromatography mass spectrometry system can include an electrospray ionization source having a vessel, which can be a pressure-resistant vessel.
[0067] In some exemplary embodiments, the liquid chromatography mass spectrometry system can include analyzing the ions using a mass spectrometer to identify protein components and characterize the protein, and the mass spectrometer can be a tandem mass spectrometer.
[0068] This disclosure provides, at least in part, an electrospray ionization source comprising a vessel having a cap with an inlet line port and an outlet line port, a sheath gas inlet, a modified desolvation gas outlet line, and an electrospray ionization probe with a sheath gas inlet.
[0069] In some exemplary embodiments, the electrospray ionization source can include a vessel having a cap with an inlet line port and an outlet line port, and a sheath gas inlet line capable of providing a sheath gas to the inlet line port.
[0070] In some exemplary embodiments, the electrospray ionization source can include a vessel having a cap with an inlet line port and an outlet line port, and a modified desolvation gas outlet line, the outlet line port of which can be connected to a sheath gas inlet of an electrospray ionization probe.
[0071] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe, which can be capable of being operated in a positive polarity mode.
[0072] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe, which can be capable of being operated in a negative polarity mode.
[0073] In some exemplary embodiments, the electrospray ionization source can include a reservoir that can be filled with an organic solvent.
[0074] In some exemplary embodiments, the electrospray ionization source can include a container that can be filled with an organic solvent and an acid.
[0075] In some exemplary embodiments, the electrospray ionization source can include a reservoir that can be filled with an organic solvent and a base.
[0076] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe with an auxiliary gas inlet.
[0077] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe having an electrospray emitter needle.
[0078] In some exemplary embodiments, the electrospray ionization source can include a vessel having a cap with an inlet line port and an outlet line port, and a sheath gas inlet line capable of providing nitrogen gas to the inlet line port.
[0079] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe having an auxiliary gas inlet, to which an auxiliary gas can be supplied.
[0080] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe having an auxiliary gas inlet, which can be supplied with nitrogen gas.
[0081] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe that includes an electrospray emitter needle, a sheath gas flow line, and an auxiliary gas flow line.
[0082] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing, and the electrospray ionization probe can be configured to direct flow in the sheath gas flow tubing coaxially with respect to the electrospray emitter needle.
[0083] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe including an electrospray emitter needle, a sheath gas flow conduit, and an auxiliary gas flow conduit, and the electrospray ionization probe can be configured to direct flow in the auxiliary gas flow conduit coaxially with respect to the electrospray emitter needle.
[0084] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization probe, which can be a heated electrospray ionization probe.
[0085] In some exemplary embodiments, the electrospray ionization source can include a vessel having a cap with an inlet line port and a sheath gas inlet line, the sheath gas inlet line can be partially inserted into the inlet line port.
[0086] In some exemplary embodiments, the electrospray ionization source can include an electrospray ionization source having a cap with an outlet line port and a modified desolvation gas outlet line, the modified desolvation gas outlet line can be partially inserted into the outlet line port.
[0087] In some exemplary embodiments, the electrospray ionization source can include a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, and the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel and into the desolvation gas outlet line.
[0088] In some exemplary embodiments, the electrospray ionization source can include a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, and the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel containing the organic solvent and into the desolvation gas outlet line.
[0089] In some exemplary embodiments, the electrospray ionization source can include a vessel with a cap having an inlet line port and an outlet line port, a sheath gas inlet line, and a modified desolvation gas outlet line, and the electrospray ionization source can be configured to allow sheath gas from the sheath gas inlet line to flow through the vessel containing the organic solvent and additional components and into the desolvation gas outlet line.
[0090] In some exemplary embodiments, the electrospray ionization source can include a vessel surrounded by a second vessel.
[0091] In some exemplary embodiments, the electrospray ionization source can include a vessel, which can be a pressure-resistant vessel.
[0092] More specifically, the present invention provides: [1] A container having a cap with an inlet line port and an outlet line port; a sheath gas inlet line for providing sheath gas to the inlet line port; A modified desolvation gas outlet line whose outlet line port can be connected to the sheath gas inlet of an electrospray ionization probe; an electrospray ionization source comprising: [2] An electrospray ionization source according to [1], wherein the container contains an organic solvent and additional chemical components; [3] an electrospray ionization source as in [2], in which the additional chemical component is an acid; [4] an electrospray ionization source of [2], in which the additional chemical component is a base; [5] The electrospray ionization source of [2], wherein the organic solvent is acetonitrile; [6] an electrospray ionization source of [3], where the acid is trifluoroacetic acid; [7] The electrospray ionization source of [4], where the base is triethylamine; [8] The electrospray ionization source of [1], wherein the electrospray ionization probe includes an auxiliary gas inlet; [9] The electrospray ionization source of [1], wherein the electrospray ionization probe includes an electrospray emitter needle;
[10] The electrospray ionization source of [1], where the sheath gas is nitrogen gas;
[11] An electrospray ionization source as in [8], where an auxiliary gas is supplied to the auxiliary gas inlet;
[12] The electrospray ionization source of [1], wherein the electrospray ionization probe includes an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing;
[13] The electrospray ionization source of
[12] , wherein the electrospray ionization probe is configured to direct flow in the sheath gas flow tubing coaxially with respect to the electrospray emitter needle;
[14] The electrospray ionization source of
[12] , wherein the electrospray ionization probe is configured to direct flow in the auxiliary gas flow tubing coaxially with respect to the electrospray emitter needle;
[15] The electrospray ionization source of [1], wherein the electrospray ionization probe is a heated electrospray ionization probe;
[16] The electrospray ionization source of [1], with the sheath gas inlet line partially inserted into the inlet line port;
[17] An electrospray ionization source as in [1], with a modified desolvation gas outlet line partially inserted into the outlet line port;
[18] An electrospray ionization source as in [1], in which sheath gas flows from a sheath gas inlet line, through a vessel containing an organic solvent, to a desolvation gas outlet line;
[19] An electrospray ionization source of [1] capable of providing a solvent flow rate of greater than about 5 μL / min for electrospray;
[20] The electrospray ionization source of [1], wherein the vessel is surrounded by a second vessel;
[21] An electrospray ionization source as in [1], which can be coupled to a liquid chromatography system;
[22] A method for characterizing proteins in a sample, comprising the steps of: a container having a cap with an inlet line port and an outlet line port; a sheath gas inlet line for providing sheath gas to the inlet line port; A modified desolvation gas outlet line whose outlet line port can be connected to the sheath gas inlet of an electrospray ionization probe; providing a sample to an inlet of an electrospray ionization source comprising: generating ions of protein constituents in the sample at the outlet of an electrospray ionization source; and characterizing the protein by analyzing the ions using a mass spectrometer to identify the protein components;
[23] The method of
[22] , wherein the container is surrounded by a second container;
[24] The method of
[22] , in which an electrospray ionization source is connected to a liquid chromatography system;
[25] The method of
[22] in which sheath gas is supplied at a pressure between 5 psi and 75 psi;
[26] The method of
[22] , where the electrospray ionization probe is in positive polarity mode;
[27] The method of
[22] , where the electrospray ionization probe is in negative polarity mode;
[28] The method of
[22] , wherein the step of characterizing the protein comprises performing intact mass analysis;
[29] The method of
[22] , wherein the step of characterizing the protein comprises a step of performing peptide mapping analysis;
[30] The method of
[22] , wherein the protein is an antibody;
[31] The method of
[22] , in which the electrospray ionization source provides a solvent flow rate for the electrospray greater than about 5 μL / min;
[32] A liquid chromatography mass spectrometry system, comprising: 1. A liquid chromatography device configured to direct a sample stream to an electrospray ionization source, comprising: An electrospray ionization source, a container having a cap with an inlet line port and an outlet line port; a sheath gas inlet line for providing a sheath gas to the inlet line port; A modified desolvation gas outlet line whose outlet line port can be connected to the sheath gas inlet of an electrospray ionization probe; and an electrospray ionization source configured to charge and desolvate the sample to form ions of constituents of the sample; Liquid chromatography equipment, A mass analyzer configured to receive the ions and perform a characterization of the mass to charge ratio of the ions. [Brief description of the drawings]
[0093] [Figure 1] FIG. 1 is a schematic diagram of the difference between top-down and bottom-up proteomics. [Diagram 2] FIG. 2 is a diagram of an electrospray ionization source that can be used for desolvation gas reformulation in a mass spectrometer according to one exemplary embodiment. [Diagram 3] FIG. 3 is a base peak chromatogram from an LC-MS analysis of a NISTmAb digest using a formic acid (FA)-based method according to an exemplary embodiment. [Figure 4] FIG. 4 is a base peak chromatogram from an LC-MS analysis of a NISTmAb digest using a trifluoroacetic acid-based method according to an exemplary embodiment. [Diagram 5] 5 is a base peak chromatogram from an LC-MS analysis of a NISTmAb digest using a trifluoroacetic acid (TFA)-based method with a PA / IPA modified desolvation gas according to one exemplary embodiment, where the MS signal from the TFA control experiment has been amplified by a factor of 2 for ease of visualization. [Figure 6] FIG. 6 shows MS intensities of six representative tryptic peptides from the NISTmAb digest using the control method (runs 1-2) and the desolvation gas reformulation method (runs 3-39), where the desolvation gas reformulation method is performed according to one exemplary embodiment. [Figure 7] FIG. 7 is a mass spectrum of the reduced heavy chain of NISTmAb using a control method performed according to an exemplary embodiment. [Figure 8] FIG. 8 is a mass spectrum of the reduced heavy chain of NISTmAb using the charge reduction method implemented according to one exemplary embodiment. [Figure 9] FIG. 9 is a deconvoluted mass spectrum of the reduced heavy chain of NISTmAb using the control method (top) and the charge reduction method (bottom) performed according to one exemplary embodiment. [Figure 10] FIG. 10 is a reduced light chain deconvolution mass spectrum of NISTmAb using the control method (top) and the charge reduction method (bottom) performed according to an exemplary embodiment. [Figure 11] FIG. 11 shows raw mass spectra of a highly heterogeneous protein with multiple O-glycans using LC-MS analysis obtained using a standard method (top) and a charge reduction method (bottom) according to an exemplary embodiment. [Figure 12]FIG. 12 is a deconvoluted mass spectrum of a highly heterogeneous protein with multiple O-glycans using LC-MS analysis obtained using charge reduction methodology according to an exemplary embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0094] Detailed Description LC-MS-based peptide mapping analysis is routinely applied to confirm the primary sequence of protein biopharmaceuticals, where protein molecules are first hydrolyzed into small peptide fragments using proteases with known specificity (although sometimes non-specific proteases can also be applied), and then the amino acid sequence of each peptide fragment is determined by LC-MS / MS analysis, taking into account the cDNA predicted sequence and the specificity of the protease used (Dick et al. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009, 877, 230-236; Bongers et al. Journal of pharmaceutical and biomedical analysis 2000, 21, 1099-1128; Mouchahoir and Schiel, Analytical and bioanalytical chemistry 2018, 410, 2111-2126). Data from peptide mapping analysis can be used to identify and quantify post-translational modifications, confirm disulfide bond linkages, and even detect amino acid substitution events that exist at very low levels (<0.1%) (Zeck et al. PloS one 2012, 7, e40328). In peptide mapping analysis of protein biopharmaceuticals, LC-MS is often coupled with ultraviolet (UV) detection to generate so-called UV fingerprints, which can be used alone as an identification assay in quality control (QC) and drug release. To effectively separate peptides with good peak shape on reversed-phase columns, trifluoroacetic acid (TFA) is often used as a mobile phase modifier due to its excellent ion-pairing ability (Shibue, et al. Journal of chromatography. A 2005, 1080, 68-75).
[0095] Unfortunately, TFA is also known for its ion suppression effect during the electrospray (ESI) process due to increased surface tension and its ability to form ion pairs with analytes in the gas phase, leading to a significant decrease in MS sensitivity (Annesley, TM Clinical chemistry 2003, 49, 1041-1044). Over the past two decades, various strategies have been investigated and implemented to mitigate the MS sensitivity loss associated with TFA. For example, the modification of TFA-containing mobile phases with acetic or propionic acid has shown significant MS signal enhancement for the bioanalysis of several basic compounds without compromising the chromatographic integrity (Shou and Naidong, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005, 825, 186-192). Post-column addition of a mixture of propionic acid and isopropanol is another commonly used strategy, which does not require modification of the LC method. However, this setup requires additional pumps, consumes large amounts of chemicals, and is not suitable for the continuous analysis of large sample sets (Apffel et al. Journal of chromatography. A 1995, 712, 177-190). Acid vapor assisted ESI in a closed spray chamber is a strategy to combat the signal suppression effect of TFA (Chen et al. Chemical communications 2015, 51, 14758-14760). However, its usefulness in the characterization of protein biopharmaceuticals is currently limited, probably because of the need for specialized ESI sources.
[0096] Finally, the reliance on using TFA to obtain good peak shapes in peptide mapping analysis has been greatly reduced by advances in reversed-phase column chemistry, especially the development of the charged surface C18 stationary phase (Lauber et al. J. Analytical chemistry 2013, 85, 6936-6944). However, replacing TFA with MS-friendly mobile phase modifiers (e.g., formic acid) inevitably reduces the retention of most peptides, and some short hydrophilic peptides become undetectable due to coelution with the solvent front, resulting in reduced sequence coverage. Nevertheless, until these new columns are routinely and widely adopted for the characterization of protein biologics, TFA-based LC-MS methods remain the mainstream in peptide mapping analysis. Considering the limitations of existing methods, we developed an effective and efficient system and method for protein characterization, as disclosed herein. A simple approach to combat TFA ion suppression during LC-MS analysis was implemented by modifying the desolvation gas with acid / base vapor and isopropanol.
[0097] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing, the specific methods and materials are described below. All publications mentioned are incorporated herein by reference.
[0098] The term "a" should be understood to mean "at least one," and the terms "about" and "approximately" should be understood to allow for standard deviation, as would be understood by one of ordinary skill in the art, and when ranges are given, the endpoints are included.
[0099] Protein biopharmaceuticals must exhibit high levels of potency, purity and low levels of structural heterogeneity, which often affect the biological activity and efficacy of pharmaceuticals. Therefore, characterization and quantification of proteins and / or impurities are important in pharmaceutical development.
[0100] In some exemplary embodiments, the present disclosure provides a method for characterizing an impurity in a sample.
[0101] The term "protein" as used herein includes any amino acid polymer having covalent amide bonds. A protein includes one or more amino acid polymer chains, commonly referred to in the art as "polypeptides." A "polypeptide" refers to a polymer composed of amino acid residues linked via peptide bonds, their associated natural structural variants, and synthetic non-natural analogs. A "synthetic peptide or polypeptide" refers to a non-natural peptide or polypeptide. A synthetic peptide or polypeptide can be synthesized, for example, using an automated polypeptide synthesizer. A variety of solid-phase peptide synthesis methods are known to those skilled in the art. A protein can contain one or more polypeptides to form a single functional biomolecule. Proteins can include biotherapeutic proteins, recombinant proteins used in research or therapy, trap proteins and other chimeric receptor Fc fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, polyclonal antibodies, human antibodies, and bispecific antibodies. In another exemplary aspect, proteins can include antibody fragments, nanobodies, recombinant antibody chimeras, cytokines, chemokines, peptide hormones, and the like. Proteins can be produced using recombinant cell-based production systems, such as insect baculovirus systems, yeast systems (e.g., Pichia sp.), mammalian systems (e.g., CHO cells and CHO derivatives such as CHO-K1 cells). For a recent review of biotherapeutic proteins and their production, see Ghaderi et al., "Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation," Biotechnol. Genet. Eng. Rev. (2012) 147-75. In some embodiments, the proteins include modifications, adducts, and other covalently attached moieties.These modifications, adducts and moieties include, for example, avidin, streptavidin, biotin, glycans (e.g., N-acetylgalactosamine, galactose, neuraminic acid, N-acetylglucosamine, fucose, mannose, and other monosaccharides), PEG, polyhistidine, FLAGtag, maltose binding protein (MBP), chitin binding protein (CBP), glutathione-S-transferase (GST) myc-epitopes, fluorescent labels and other dyes, etc. Proteins can be classified based on composition and solubility, and thus proteins can include simple proteins, such as globular proteins and fibrous proteins; complex proteins, such as nucleoproteins, glycoproteins, mucoproteins, chromoproteins, phosphoproteins, metalloproteins, and lipoproteins; and derived proteins, such as primary derived proteins and secondary derived proteins.
[0102] In some exemplary embodiments, the protein may be an antibody, a bispecific antibody, a multispecific antibody, an antibody fragment, a monoclonal antibody, or a combination thereof.
[0103] As used herein, the term "antibody" includes immunoglobulin molecules that contain four polypeptide chains, i.e., two heavy (H) chains and two light (L) chains that are interconnected by disulfide bonds, and multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (referred to herein as HCVR or V H The heavy chain constant region is made up of three domains, C H 1. C H 2 and C H Each light chain comprises a light chain variable region (referred to herein as LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H Area and V L The regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs) interspersed with regions of high conserved regions called framework regions (FRs). Hand V L is composed of three CDRs and four FRs arranged in the following order from amino terminus to carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In various embodiments of the present invention, the FRs of the anti-big-ET-1 antibody (or antigen-binding portion thereof) may be identical to the human germline sequence or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on the analysis of aligning two or more CDRs. The term "antibody" as used herein also includes antigen-binding fragments of complete antibody molecules. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, include any naturally occurring, enzymatically obtainable, synthetic, or genetically modified polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be derived, for example, from intact antibody molecules using any suitable standard technique, such as, for example, proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding the variable and optionally constant domains of the antibody. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated, for example, to place one or more variable and / or constant domains in the appropriate configuration, or chemically or using molecular biology techniques, for example, to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
[0104] As used herein, an "antibody fragment" includes a portion of an intact antibody, such as, for example, an antigen-binding or variable region of an antibody. Examples of antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, scFv fragments, Fv fragments, dsFv diabodies, dAb fragments, Fd' fragments, Fd fragments, and isolated complementarity determining regions (CDRs), as well as triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments. An Fv fragment is a combination of the variable regions of the heavy and light immunoglobulin chains, and an ScFv protein is a recombinant single-chain polypeptide molecule in which the variable regions of the light and heavy immunoglobulin chains are linked by a peptide linker. In some exemplary embodiments, an antibody fragment contains sufficient amino acid sequence of the parent antibody from which it is derived to bind to the same antigen as the parent antibody. In some exemplary embodiments, the fragment binds to an antigen with an affinity comparable to that of the parent antibody and / or competes with the parent antibody for binding to the antigen. Antibody fragments can be produced by any means. For example, antibody fragments can be produced enzymatically or chemically by fragmentation of an intact antibody and / or recombinantly produced from a gene encoding a partial antibody sequence. Alternatively or additionally, antibody fragments can be produced synthetically in whole or in part. Antibody fragments can optionally include single chain antibody fragments. Alternatively or additionally, antibody fragments can include multiple chains linked together, such as by disulfide bonds. Antibody fragments can optionally include multimolecular complexes. Functional antibody fragments typically include at least about 50 amino acids, more typically at least about 200 amino acids.
[0105] The phrase "bispecific antibodies" encompasses antibodies capable of selectively binding to two or more epitopes. Bispecific antibodies generally comprise two different heavy chains, each of which specifically binds to a different epitope on two different molecules (e.g., antigens) or on the same molecule (e.g., on the same antigen). When a bispecific antibody can selectively bind to two different epitopes (a first epitope and a second epitope), the affinity of the first heavy chain for the first epitope is generally at least one to two or three or four orders of magnitude lower than the affinity of the first heavy chain for the second epitope, or vice versa. The epitopes recognized by bispecific antibodies can be on the same target or on different targets (e.g., the same protein or different proteins). Bispecific antibodies can be generated, for example, by combining heavy chains that recognize different epitopes of the same antigen. For example, nucleic acid sequences encoding heavy chain variable sequences that recognize different epitopes of the same antigen can be fused to nucleic acid sequences encoding different heavy chain constant regions, and such sequences can be expressed in a cell that expresses an immunoglobulin light chain. A typical bispecific antibody has three heavy chain CDRs, each followed by a CDR. H 1 domain, hinge, C H 2 domain and C HBsAbs have two heavy chains with a Fc domain and an immunoglobulin light chain that either does not confer antigen-binding specificity but can associate with each heavy chain, or can associate with each heavy chain and bind to one or more of the epitopes bound by the heavy chain antigen-binding region, or can associate with each heavy chain and enable one or both of the heavy chains to bind to one or both epitopes. BsAbs can be divided into two major classes, those that retain the Fc region (IgG-like) and those that lack the Fc region, the latter being usually smaller than the Fc-containing IgG and IgG-like bispecific molecules. IgG-like bsAbs can have various formats, including but not limited to triomabs, knobs into holes IgG (kih IgG), crossMabs, orth-Fab IgG, dual-variable domains Ig (DVD-Ig), two-in-one or dual action Fab (DAF), IgG-single chain Fv (IgG-scFv), or κλ-body. Non-IgG-like various formats include tandem scFv, diabody formats, single chain diabodies, tandem diabodies (TandAbs), dual-affinity retargeting molecule (DART), DART-Fc, nanobodies, or antibodies produced by dock-and-lock (DNL) technology. Fan et al. and Kontermann and Brinkmann have published detailed reviews on bispecific antibodies (Fan et al. “Bispecific antibodies and their applications” J. Hematol. Oncol. (2015) 8:130; Kontermann and Brinkmann, “Bispecific antibodies” Drug Discov. Today (2015) 20:838-847).Methods for producing BsAbs include, but are not limited to, quadroma technology, which is based on pairwise cell fusion of two different hybridoma cell lines, chemical conjugation, which requires a chemical cross-linking agent, and genetic approaches utilizing recombinant DNA technology. Examples of bsAbs include those disclosed in the following patent applications, which are incorporated herein by reference in their entirety: U.S. Patent Application Publication No. 8,586,713, filed June 25, 2010; U.S. Patent Application Publication No. 2013 / 0045492, filed June 5, 2012; U.S. Patent Application Publication No. 9,657,102, filed September 19, 2013; U.S. Patent Application Publication No. 2016 / 0024147, filed July 24, 2015; U.S. Patent Application Publication No. 2018 / 0112001, filed September 22, 2017 ... No. 2018 / 0104357, filed Dec. 22, U.S. Patent Application Publication No. 2017 / 0174779, filed Dec. 21, 2016, U.S. Patent Application Publication No. 2017 / 0174781, filed Dec. 21, 2016, U.S. Patent Application No. 10,179,819, filed July 29, 2016, and U.S. Patent Application Publication No. 2018 / 0134794, filed Nov. 15, 2017. Low levels of homodimeric impurities may be present at several steps during the manufacture of bispecific antibodies. Detection of such homodimeric impurities may be challenging when performed using intact mass spectrometry due to their low abundance and the fact that these impurities co-elute with the major species when performed using conventional liquid chromatography methods.
[0106] As used herein, a "multispecific antibody" or "Mab" refers to an antibody that has binding specificities for at least two different antigens. Although such molecules typically only bind to two antigens (i.e., bispecific antibodies, BsAbs), antibodies with additional specificities, such as trispecific antibodies and KIH Trispecifics, can also be addressed by the systems and methods disclosed herein.
[0107] The term "monoclonal antibody" as used herein is not limited to antibodies produced by hybridoma technology. Monoclonal antibodies can be obtained from a single clone, including any eukaryotic, prokaryotic or phage clone, by any means available or known in the art. Monoclonal antibodies useful in the present disclosure can be prepared using a wide variety of techniques known in the art, including the use of hybridoma technology, recombinant technology and phage display technology, or a combination thereof.
[0108] Impurities can form during many stages of biopharmaceutical production. Biotechnology-derived impurities can be extremely difficult to characterize and quantify because they are often present at very low levels and they can represent very complex chemical species or mixtures of chemical species. It can also be very difficult to obtain authentic versions of impurity peaks. However, full characterization of trace amounts of impurity proteins is a time-consuming, lengthy, and often very expensive process. In many cases, impurities can include variants, isoforms, degradation products, product-derived impurities, process-derived impurities, minor post-translational modifications, aggregates, or clipped fragments of intact recombinant proteins.
[0109] In some exemplary embodiments, the present disclosure provides a method for characterizing proteins in a sample.
[0110] The term "impurities" as used herein may include any undesired proteins present in a biopharmaceutical product. Impurities may include process-derived impurities and product-derived impurities. Impurities may further be of known structure, partially characterized, or unidentified. Process-derived impurities may originate from the manufacturing process and may include three major categories: cell substrate-derived, cell culture-derived, and downstream-derived. Cell substrate-derived impurities include, but are not limited to, proteins and nucleic acids (host cell genomic DNA, vector DNA, or total DNA) from the host organism. Cell culture-derived impurities include, but are not limited to, inducers, antibiotics, serum, and other media components. Downstream-derived impurities include, but are not limited to, enzymes, chemical and biochemical treatment reagents (e.g., cyanogen bromide, guanidine, oxidizing and reducing agents), inorganic salts (e.g., heavy metals, arsenic, non-metal ions), solvents, carriers, ligands (e.g., monoclonal antibodies), and other leachables. Target-derived impurities (e.g. precursors, certain degradation products) may be molecular variants arising during production and / or storage that do not have comparable properties to those of the target substance in terms of activity, potency and safety. Such variants may require significant efforts for isolation and characterization to identify the type of modification. Target-derived impurities may include truncations, modifications and aggregates. Truncations are formed by hydrolytic enzymes or chemicals that catalyze the cleavage of peptide bonds. Modifications include, but are not limited to, deamidations, isomers, S-S bond mismatches, oxidations or altered complexes (e.g. glycosylation, phosphorylation). Modifications may also include any post-translational modifications. Aggregates include dimers and higher order multimers of the target substance.(Q6B "Specifications: Test Procedures and Acceptance Criteria for Biotechnological / Biological Products", ICH August 1999, US Dept. of Health and Humans Services).
[0111] The general term "post-translational modification", or "PTM", as used herein, refers to a covalent modification that a polypeptide undergoes during (co-translational modification) or after (post-translational modification) ribosomal synthesis. PTMs are generally introduced by specific enzymes or specific enzymatic pathways. Many of them occur at special characteristic protein sequences (e.g., signature sequences) within the protein backbone. Hundreds of PTMs have been documented, and these modifications always affect some aspect of the protein's structure or function (Walsh, G. "Proteins" (2014), 2nd Edition, published by Wiley and Sons, Ltd., ISBN:9780470669853). Various post-translational modifications include cleavage, N-terminal elongation, proteolysis, N-terminal acylation, biotinylation (acylation of lysine residues with biotin), C-terminal amidation, glycosylation, iodination, covalent attachment of prosthetic groups, acetylation (addition of an acetyl group, usually occurring at the N-terminus of a protein), alkylation (addition of an alkyl group, e.g., methyl, ethyl, or propyl, usually occurring at a lysine or arginine residue), methylation, adenylation, ADP-ribosylation, covalent cross-links within or between polypeptide chains, sulfonation, prenylation, vitamin C-dependent modifications (hydroxylation of proline and lysine and amidation of the carboxy terminus), and vitamin K as a cofactor in the carboxylation of glutamic acid residues to form γ-carboxyglutamic acid (glu residues). These modifications include, but are not limited to, vitamin K-dependent modifications resulting in covalent attachment of a phosphate group to either asparagine, hydroxylysine, serine or threonine, resulting in glycoproteins, glutamylation (covalent attachment of a glutamic acid residue), glycylation (covalent attachment of a glycine residue), glycosylation (addition of a glycosyl group to either asparagine, hydroxylysine, serine or threonine resulting in glycoproteins), isoprenylation (addition of an isoprenoid group such as farnesol and geranylgeraniol), lipoylation (addition of a lipoic acid functionality), phosphopantetheinylation (addition of a 4'-phosphopantetheinyl moiety from coenzyme A, which occurs in fatty acid, polyketide, nonribosomal peptide and leucine biosynthesis), phosphorylation (addition of a phosphate group, usually to serine, tyrosine, threonine or histidine), and sulfation (addition of a sulfate group, usually to a tyrosine residue).Post-translational modifications that change the chemical properties of amino acids include, but are not limited to, citrullination (e.g., conversion of arginine to citrulline by deimination) and deamidation (e.g., conversion of glutamine to glutamic acid or asparagine to aspartic acid). Post-translational modifications that involve structural changes include, but are not limited to, the formation of disulfide bridges (covalent linkage of two cysteine amino acids) and proteolytic cleavage (cleavage of a protein at a peptide bond). Certain post-translational modifications involve the addition of other proteins or peptides, such as ISGylation (covalent linkage to ISG15 protein (interferon stimulated gene)), SUMOylation (covalent linkage to SUMO protein (Small Ubiquitin-related MOdifier)), and ubiquitination (covalent linkage to the protein ubiquitin). For a more detailed controlled vocabulary of PTMs maintained by UniProt, see http: / / www.uniprot.org / docs / ptmlist.
[0112] As used herein, a "mutant protein" or "protein variant" or "variant" can include a protein that differs from a target protein by virtue of at least one amino acid modification. A protein variant can refer to the protein itself, a composition comprising the protein, or the amino acid sequence encoding it. Preferably, a protein variant has at least one amino acid modification compared to the parent protein, such as about 1 to about 10 amino acid modifications compared to the parent, preferably about 1 to about 5 amino acid modifications. A protein variant sequence herein will preferably have at least about 80% homology, most preferably at least about 90% homology, and even more preferably at least about 95% homology to the parent protein sequence.
[0113] Comprehensive characterization of proteins can meet protein safety standards set by regulatory authorities and can help ensure the efficacy of protein drugs. Therefore, proteomic approaches are important in the biopharmaceutical industry, where they help in protein identity confirmation, monitoring protein modifications such as PTMs and protein variants, monitoring degradation events such as oxidation or deamidation, etc. Proteomic approaches can be differentiated according to the level at which the analysis is performed (see Figure 1).
[0114] As used herein, "intact mass analysis" includes top-down experiments in which proteins are identified as intact proteins (see Figure 1, left). Intact mass analysis can minimize sample preparation and preserve information that is sometimes lost in other proteomic strategies, such as the connectivity of multiple PTMs.
[0115] Some proteomics experiments rely on the digestion of proteins into peptides prior to MS analysis. As used herein, "peptide mapping analysis" includes experiments in which proteins undergo digestion followed by separation of the resulting peptides and their analysis, preferably using LC-MS (see FIG. 1, right). In some exemplary embodiments, peptide mapping analysis can be applied to confirm the primary sequence of protein biologics, where protein molecules are first hydrolyzed into small peptide fragments using hydrolytic agents, and then the amino acid sequence of each peptide fragment is determined by LC-MS / MS analysis, taking into account the cDNA predicted sequence and the specificity of the protease used. Data from peptide mapping analysis can also be used to identify and quantify post-translational modifications, confirm disulfide bond linkages, and even detect amino acid substitution events that exist at very low levels (<0.1%) (Zeck et al. PloS one 2012, 7, e40328). In peptide mapping analysis of protein biologics, LC-MS is often coupled with ultraviolet (UV) detection to generate a so-called UV fingerprint, which can be used alone as an identification assay in quality control (QC) and drug release.
[0116] The term "digestion" as used herein refers to the hydrolysis of one or more peptide bonds of a protein. There are several approaches to perform digestion of proteins in a sample, for example enzymatic or non-enzymatic digestion, using a suitable hydrolytic agent. The term "hydrolytic agent" as used herein refers to any one or any combination of a number of different agents capable of performing digestion of proteins. Non-limiting examples of hydrolytic agents capable of performing enzymatic digestion include trypsin, endoproteinase Arg-C, endoproteinase Asp-N, endoproteinase Glu-C, outer membrane protease T (OmpT), immunoglobulin degrading enzyme (IdeS) of Streptococcus pyogenes, chymotrypsin, pepsin, thermolysin, papain, pronase, and protease from Aspergillus Saitoi. Non-limiting examples of hydrolysis agents that can perform non-enzymatic digestion include high temperature, microwave, ultrasound, high pressure, infrared, solvents (non-limiting examples are ethanol and acetonitrile), immobilized enzyme digestion (IMER), magnetic particle immobilized enzymes, and on-chip immobilized enzymes.For a recent review that discusses available techniques for protein digestion, see Switazar et al., "Protein Digestion: An Overview of the Available Techniques and Recent Developments," J. Proteome Research 2013, 12, 1067-1077.One or a combination of hydrolysis agents sequence-specifically cleaves peptide bonds in proteins or polypeptides to generate a predictable collection of shorter peptides.
[0117] There are several approaches that can be used to digest proteins. One widely accepted method for digesting proteins in a sample involves the use of proteases. Many proteases are available, each of which has its own characteristics in terms of specificity, efficiency and optimal digestion conditions. Proteases refer to both endopeptidases and exopeptidases, which are classified based on the ability of the protease to perform cleavage at non-terminal or terminal amino acids in a peptide. Alternatively, proteases also refer to six different classes, namely aspartic proteases, glutamic proteases, and metalloproteases, cysteine proteases, serine proteases and threonine proteases, which are classified based on catalytic mechanism. The terms "protease" and "peptidase" are used interchangeably to refer to enzymes that hydrolyze peptide bonds. Proteases can also be classified into specific and non-specific proteases. As used herein, the term "specific protease" refers to a protease that has the ability to cleave a peptide substrate at a specific amino acid side chain of the peptide. As used herein, the term "non-specific protease" refers to a protease that has a reduced ability to cleave a peptide substrate at a specific amino acid side chain of the peptide. Cleavage preference may be determined based on the ratio of the number of specific amino acids as cleavage sites to the total number of cleaved amino acids in the protein sequence.
[0118] Proteins can optionally be prepared prior to characterization. In some exemplary embodiments, protein preparation comprises a step of protein digestion. In some specific exemplary embodiments, protein preparation comprises a step of protein digestion, which can be performed with trypsin.
[0119] In some exemplary embodiments, protein preparation can include steps to denature the protein, reduce the protein, buffer the protein, and / or desalt the sample prior to the protein digestion step. These steps can be accomplished in any suitable manner, as desired.
[0120] A wide variety of LC-MS based assays can be performed to characterize various protein attributes using peptide mapping analysis or intact mass analysis.
[0121] As used herein, the term "liquid chromatography" refers to a process in which a liquid-borne mixture of chemicals can be separated into components as a result of differences in the distribution of the chemicals as they flow around or over a stationary or stationary phase. Non-limiting examples of liquid chromatography include reversed-phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, and hydrophobic chromatography.
[0122] The term "mass spectrometer" as used herein refers to an instrument capable of detecting specific molecular species and accurately measuring their mass. The term may encompass any molecular detector into which a polypeptide or peptide may be eluted for detection and / or characterization. A mass spectrometer consists of three main parts: an ion source, a mass analyzer, and a detector. The role of the ion source is to create gas phase ions. Analyte atoms, molecules, or clusters can be transferred into the gas phase and ionized simultaneously (in the case of electrospray ionization). The choice of ion source depends on the application.
[0123] As used herein, the term "electrospray ionization", or "ESI", refers to a process of spray ionization in which dissolved cations or anions are transferred to the gas phase by the formation and desolvation at atmospheric pressure of a stream of highly charged droplets obtained by applying a potential difference between the tip of an electrospray emitter needle containing the solution and a counter electrode. There are three main steps in the generation of gas phase ions from dissolved electrolyte ions: (a) generation of charged droplets at the ES infusion tip, (b) shrinkage of the charged droplets by solvent evaporation and repeated droplet breakup resulting in small highly charged droplets capable of generating gas phase ions, and (c) a mechanism for the generation of gas phase ions from extremely small highly charged droplets. Steps (a)-(c) generally occur in the atmospheric pressure region of the instrument.
[0124] The term "electrospray ionization source" as used herein refers to an electrospray ionization system that can be compatible with a mass spectrometer used for mass analysis of proteins. In electrospray ionization, an electrospray emitter needle has its opening located near the entrance of the spectrometer. A sample containing a protein of interest can be injected through the electrospray emitter needle. An electric potential between the electrospray emitter needle opening and an opening leading to the mass analyzer forms a spray of solution ("electrospray"). Electrospray can be performed at atmospheric pressure, giving highly charged droplets of the solution. An electrospray ionization source can be configured to operate in any of several atmospheric pressure ionization (API) modes, such as electrospray ionization (ESI), heated electrospray ionization (H-ESI), atmospheric pressure chemical ionization (APCI), and atmospheric pressure photoionization (APPI). The electrospray injection mechanism can be optionally automated to perform sample aspiration, sample dispensing, sample delivery, and / or to spray the sample. Electrospray ionization probes can generate charged aerosol droplets containing sample ions. The ESI probe can accommodate liquid flows of 5 μL / min to 1 mL / min without splitting.
[0125] The ESI probe can include an ESI sample tube, an electrospray emitter needle, a nozzle, and a manifold. Sample and solvent can enter the ESI probe through the sample tube. The sample tube can be a short section of OD fused silica tubing that runs from a stainless steel ground to the end of the ESI needle. The electrospray emitter needle can have a large negative or positive voltage applied to it, spraying the sample solution into a fine mist of charged droplets. The ESI nozzle can direct a flow of sheath gas and auxiliary gas at the droplets. The ESI manifold can house the ESI nozzle, the electrospray emitter needle, a sheath gas inlet, an auxiliary gas inlet, sheath gas piping, and auxiliary gas piping. The sheath gas piping and auxiliary gas piping can deliver drying gas to the nozzle. The sheath gas inlet and auxiliary gas inlet in the manifold can be connected to a sheath gas inlet line and an auxiliary gas inlet line, respectively. Alternatively, the sheath gas inlet and auxiliary gas inlet in the manifold can be connected to the modified desolvation gas outlet line and auxiliary gas inlet line, respectively. The connection between the gas inlets and the gas inlet lines can be made using adapter fittings.
[0126] As used herein, the term "nanoelectrospray" or "nanospray" refers to electrospray ionization performed at extremely low solvent flow rates, typically no more than a few hundred nanoliters of sample solution per minute, often without the use of exogenous solvent delivery.
[0127] "Mass spectrometer" as used herein refers to a device that can separate chemical species, i.e. atoms, molecules or clusters according to their mass.Non-limiting examples of mass spectrometers that can be used for rapid protein sequencing are time-of-flight (TOF), magnetic / electric sector, quadrupole mass filter (Q), quadrupole ion trap (QIT), orbitrap, Fourier transform ion cyclotron resonance (FTICR), and also accelerator mass spectrometry (AMS) techniques.
[0128] As used herein, "mass-to-charge ratio," or "m / z," is used to denote the dimensionless quantity formed by dividing the mass of an ion in unified atomic mass units by its charge (regardless of sign). In general, the charge state depends on the method of ionization (electrospray ionization, ESI, tends to favor multiple ionization, which is less frequent with MALDI), the length of the peptide (longer peptides have more groups (basic residues) that can attach additional protons), the sequence of the peptide (some amino acids, e.g., Arg or Lys, are more prone to ionization than others), instrument settings, solvent pH, and solvent composition.
[0129] As used herein, the term "tandem mass spectrometry" refers to a technique that can obtain structural information about sample molecules using multiple stages of mass selection and mass separation. The prerequisites are that the sample molecules can be transferred into the gas phase, that they can be ionized intact, and that after the initial mass selection step they can be induced to fragment in a predictable and controllable manner. Multistage MS / MS, or MS n First, precursor ions are selected and isolated (MS 2 ), which is then fragmented to isolate the primary fragment ions (MS 3 ), which is then fragmented to isolate secondary fragments (MS 4), as long as it is possible to obtain meaningful information or as long as fragment ion signals are detectable. Tandem MS has been successfully performed with a wide variety of analytical instrument combinations. The choice of analytical instrument combination for a given application may be determined by a number of different factors, such as sensitivity, selectivity, and speed, as well as size, cost, and availability. The two main categories of tandem MS techniques are tandem-in-space and tandem-in-time, although there are also hybrid types in which tandem-in-time instruments are spatially coupled or coupled with spatial tandem instruments.
[0130] A spatial tandem mass spectrometer consists of an ion source, a precursor ion activation device, and at least two non-trapping mass analyzers. A specific m / z separation function can be designed such that ions are selected in one section of the instrument, dissociated in an intermediate region, and then the product ions are sent to another analyzer for m / z separation and data acquisition.
[0131] In a temporal tandem mass spectrometer, ions produced in an ion source can be trapped, isolated, fragmented and m / z separated in the same physical device.
[0132] The term "quadrupole-orbitrap hybrid mass spectrometer" as used herein refers to a hybrid system that is created by coupling a quadrupole mass spectrometer to an orbitrap mass spectrometer. A time-series tandem experiment using a quadrupole-orbitrap hybrid mass spectrometer begins with the ejection of all ions from the quadrupole mass spectrometer except for those within a selected narrow m / z range. The selected ions are inserted into the orbitrap and can be fragmented, most often by low-energy CID. Fragments within the trap's m / z tolerance range should remain in the trap and can obtain MS-MS spectra. Similar hybrid systems, such as but not limited to QIT-FTICR and Qq-FTICR, can be used for rapid protein sequencing.
[0133] It will be understood that the present invention is not limited to any of the liquid chromatographs or mass spectrometers mentioned above, and that any liquid chromatograph or mass spectrometer may be selected by any suitable means.
[0134] Protein characterization The peptides identified by mass spectrometry can be used as surrogate representatives of intact proteins and their post-translational modifications. They can be used for protein characterization by correlating experimental MS / MS data with theoretical MS / MS data generated from possible peptides in protein sequence databases. Characterization includes, but is not limited to, sequencing the amino acids of protein fragments, determining protein sequencing, determining protein de novo sequencing, locating or identifying post-translational modifications, or comparability analysis, or a combination thereof.
[0135] As used herein, the term "protein de novo sequencing" refers to the procedure for determining the amino acid sequence of peptide without relying on information obtained from other sources.Due to the high level of sensitivity of mass spectrometry, this technique can provide crucial information that is often beyond the capabilities of traditional sequencing methods.
[0136] As used herein, the term "protein sequence coverage" refers to the percentage of a protein sequence that is covered by identified peptides. Percent coverage can be calculated by dividing the number of amino acids in all peptides found by the total number of amino acids in the entire protein sequence.
[0137] The term "database" as used herein refers to a bioinformatics tool that allows uninterpreted MS-MS spectra to be searched against all possible sequences in the database. Non-limiting examples of such tools include Mascot (http: / / www.matrixscience.com), Spectrum Mill (http: / / www.chem.agilent.com), PLGS (http: / / www.waters.com), PEAKS (http: / / www.bioinformaticssolutions.com), Proteinpilot (http: / / download.appliedbiosystems.com / / proteinpilot), Phenyx (http: / / www.phenyx-ms.com), Sorcerer (http: / / www.sagenresearch.com), OMSSA (http: / / www.pubchem.ncbi.nlm.nih.gov / omssa / ), X!Tandem (http: / / www.thegpm.org / TANDEM / ), Protein Prospector (http: / / www.http: / / prospector.ucsf.edu / prospector / mshome.htm), Byonic (https: / / www.proteinmetrics.com / products / byonic) or Sequest (http: / / fields.scripps.edu / sequest).
[0138] Exemplary embodiments Embodiments disclosed herein provide compositions, methods and systems for the rapid characterization of proteins in a sample.
[0139] As used herein, the terms "include," "includes," and "including" are meant to be open-ended and are understood to mean "comprise," "comprises," and "comprising," respectively.
[0140] In some exemplary embodiments, the present disclosure provides a liquid chromatography mass spectrometry system that includes (i) a liquid chromatography device, (ii) an electrospray ionization source, and (iii) a mass spectrometer.
[0141] In some exemplary embodiments, the present disclosure provides an electrospray ionization source 100 including (i) a container 110, (ii) a sheath gas inlet line 120, (iii) a modified desolvation gas outlet line 130, and (iv) an electrospray ionization probe 140 (see FIG. 2 ).
[0142] In some exemplary embodiments, the present disclosure provides a method for characterizing proteins in a sample, comprising the steps of: (i) providing a sample to an inlet of an electrospray ionization source 100; (ii) generating ions of protein constituents in the sample at an outlet of the electrospray ionization source; and (iii) analyzing the ions using a mass spectrometer to identify the protein constituents and characterize the proteins.
[0143] Non-limiting examples of liquid chromatography devices can include reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophilic interaction chromatography, and hydrophobic chromatography.
[0144] In some exemplary embodiments, the sheath gas inlet line 120 can be a Teflon tubing.
[0145] In some exemplary embodiments, the sheath gas inlet line 120 can be a flexible stainless steel tube.
[0146] In some exemplary embodiments, the sheath gas inlet line 120 can be a tube made using polyetheretherketone.
[0147] In some exemplary embodiments, the modified desolvation gas outlet line 130 can be a Teflon tubing.
[0148] In some exemplary embodiments, the modified desolvated gas outlet line 130 can be a flexible stainless steel pipe.
[0149] In some exemplary embodiments, the modified desolvated gas outlet line 130 can be a tube made using polyetheretherketone.
[0150] In some exemplary embodiments, the container 110 can include a cap 150. The cap is safe for use with the mobile phase.
[0151] In some exemplary embodiments, the container 110 can include a cap 150, which can form an airtight seal between the cap and the container. Non-limiting examples of caps that can be used include Analytical Sales' Canary-Safe Cap, Restek's Eco-cap bottle top, Restek's Opti-cap bottle top, and VWR's inert mobile phase bottle cap cap.
[0152] In some exemplary embodiments, the cap 150 may include a screw cap.
[0153] In some exemplary embodiments, the cap 150 can be made of a polytetrafluoroethylene (PTFE) material.
[0154] In some exemplary embodiments, the cap 150 may further include an O-ring to ensure an airtight seal between the cap and the container 110 .
[0155] In some exemplary embodiments, the cap 150 on the container 110 can have at least one port for a tube. In one aspect, the cap 150 on the container 110 can have two ports for a tube.
[0156] In some exemplary embodiments, the cap 150 on the container 110 can have at least one inlet port 160 .
[0157] In some exemplary embodiments, the cap 150 on the container 110 can have at least one outlet port 170 .
[0158] In some exemplary embodiments, the electrospray ionization probe 140 of the electrospray ionization source 100 can include a sheath gas inlet 180 .
[0159] In some exemplary embodiments, the electrospray ionization source 100 can include a vessel 110 having a cap 150 with an inlet line port 160 and an outlet line port 170, and a sheath gas inlet line 120 capable of providing a sheath gas to the inlet line port 160.
[0160] In some exemplary embodiments, the electrospray ionization source 100 can include a vessel 110 having a cap 150 with an inlet line port 160 and an outlet line port 170, and a modified desolvation gas outlet line 130, the outlet line port 170 of which can be connected to a sheath gas inlet 180 of the electrospray ionization probe 140.
[0161] In some exemplary embodiments, the electrospray ionization probe 140 may be capable of operating in a positive polarity mode.
[0162] In some exemplary embodiments, the electrospray ionization probe 140 may be capable of operating in a negative polarity mode.
[0163] In some exemplary embodiments, the electrospray ionization probe 140 can include an auxiliary gas inlet 190 .
[0164] In some exemplary embodiments, the electrospray ionization probe 140 can further include an electrospray emitter needle.
[0165] In some exemplary embodiments, a sheath gas can be provided by a sheath gas source 200 through a sheath gas inlet line 120 to a vessel 110 having a cap 150 with an inlet line port 160. Non-limiting examples of sheath gases include air, nitrogen.
[0166] In some exemplary embodiments, an auxiliary gas can be provided by an auxiliary gas source 210 to the auxiliary gas inlet 190 of the electrospray ionization probe 140 through an auxiliary gas inlet line 220. Non-limiting examples of auxiliary gases include air and nitrogen.
[0167] In some exemplary embodiments, the sheath gas that may be provided by a sheath gas source 200 through a sheath gas inlet line 120 to a vessel 110 having a cap 150 with an inlet line port 160 can be nitrogen gas.
[0168] In some exemplary embodiments, the auxiliary gas, which may be provided by auxiliary gas source 210 to auxiliary gas inlet 190 of electrospray ionization probe 140 through auxiliary gas inlet line 220, may be nitrogen gas.
[0169] In some exemplary embodiments, electrospray ionization probe 140 can include an electrospray emitter needle, sheath gas flow tubing, and auxiliary gas flow tubing.
[0170] In some exemplary embodiments, the electrospray ionization source 110 can include an electrospray ionization probe 140 that can include an electrospray emitter needle, a sheath gas flow tubing, and an auxiliary gas flow tubing, and the electrospray ionization probe can be configured to direct flow in the sheath gas flow tubing coaxially with respect to the electrospray emitter needle.
[0171] In some exemplary embodiments, the electrospray ionization probe 140 can be configured to direct flow in the auxiliary gas flow tubing coaxially with respect to the electrospray emitter needle.
[0172] In some exemplary embodiments, the electrospray ionization probe 140 can be a heated electrospray ionization probe.
[0173] In some exemplary embodiments, the electrospray ionization probe 140 can be automated to perform sample aspiration, sample dispensing, sample delivery, and / or to spray the sample.
[0174] In some exemplary embodiments, the vessel 110 includes a cap 150 with an inlet line port 160 and a sheath gas inlet line 120 , which may be partially inserted into the inlet line port 160 .
[0175] In some exemplary embodiments, a cap 150 having an outlet line port 170 and a modified desolvation gas outlet line 130 , the modified desolvation gas outlet line 130 can be partially inserted into the outlet line port 170 .
[0176] In some exemplary embodiments, the electrospray ionization source 100 can be configured to allow sheath gas from the sheath gas inlet line 120 to flow through the vessel 100 and into the desolvation gas outlet line 130 .
[0177] In some exemplary embodiments, the container 100 can be surrounded by a second container 230. In some specific exemplary embodiments, the second container 230 can be made of polyethylene. In one aspect, the second container 230 can provide shatterproof protection for a glass bottle. In another aspect, the second container 230 can have an opening at the top.
[0178] In some exemplary embodiments, the container 110 can be made from a borosilicate glass material.
[0179] In some exemplary embodiments, the volume of the container 110 can range from about 10 ml to about 5000 ml. In one aspect, the volume of the container 110 can be about 10 ml, about 20 ml, about 30 ml, about 40 ml, about 50 ml, about 60 ml, about 70 ml, about 80 ml, about 90 ml, about 100 ml, about 110 ml, about 120 ml, about 130 ml, about 140 ml, about 150 ml, about 160 ml, about 170 ml, about 180 ml, about 190 ml, about 200 ml, about 210 ml, about 220 ml, about 230 ml, about 240 ml, about 250 ml, about 260 ml, about 270 ml, about 280 ml, about 290 ml, about 300 ml, about 310 ml, about 320 ml, about 330 ml, about 340 ml, about 350 ml, about 360 ml, about 370 ml, about 380 ml, about 390 ml, about 400 ml, about 410 ml, about 420 ml, about 430 ml, about 440 ml, about 450 ml, about 460 ml, about 470 ml, about 480 ml, about 490 ml, about 500 ml, about 510 ml, about 520 ml, about 530 ml, about 540 ml, about 550 ml, about 560 ml, about 570 ml, about 580 ml, about 590 ml, about 600 ml, about 610 ml, about 620 ml, about 630 ml, about 640 ml, about 650 ml, about 660 ml, about 670 ml, about 680 The volume of the liquid may be about 0 ml, about 360 ml, about 370 ml, about 380 ml, about 390 ml, about 400 ml, about 410 ml, about 420 ml, about 430 ml, about 440 ml, about 450 ml, about 460 ml, about 470 ml, about 480 ml, about 490 ml, about 1000 ml, about 1100 ml, about 1200 ml, about 1300 ml, about 1400 ml, about 1500 ml, about 1600 ml, about 1700 ml, about 1800 ml, about 1900 ml, about 2000 ml, about 2500 ml, about 3000 ml, about 3500 ml, about 4000 ml, about 4500 ml, or about 5000 ml.
[0180] In some exemplary embodiments, the vessel 110 can be a pressure vessel.
[0181] In some exemplary embodiments, the vessel 110 can have a pressure resistance of at least about 0.5 bar (gauge pressure). In one aspect, the vessel 110 can have a pressure resistance of at least about 0.5 bar (gauge pressure), at least about 0.6 bar (gauge pressure), at least about 0.7 bar (gauge pressure), at least about 0.8 bar (gauge pressure), at least about 0.9 bar (gauge pressure), at least about 1 bar (gauge pressure), at least about 1.1 bar (gauge pressure), at least about 1.2 bar (gauge pressure), at least about 1.3 bar (gauge pressure), at least about 1.4 bar (gauge pressure), at least about 1.5 bar (gauge pressure), at least about 1.6 bar (gauge pressure), at least about 1.7 bar (gauge pressure), at least about 1.8 bar (gauge pressure), at least about 1.9 bar (gauge pressure), or at least about 2.0 bar (gauge pressure).
[0182] In some exemplary embodiments, the container 110 can be filled with at least one organic solvent. Non-limiting examples of organic solvents include acetonitrile, propanol, isopropanol, water, and methanol.
[0183] In some exemplary embodiments, the container 110 can be filled with at least one acid. Non-limiting examples of acids include acetic acid, propionic acid, and formic acid.
[0184] In some exemplary embodiments, the container 110 can be filled with at least one base. Non-limiting examples of bases include ammonia, diethylamine, triethylamine, N,N-diisopropylethylamine (DIPEA), and piperidine. In some exemplary embodiments, the container 110 can be filled with at least one organic solvent and at least one acid.
[0185] In some exemplary embodiments, the vessel 110 can be filled with at least one organic solvent and at least one base.
[0186] In some exemplary embodiments, the electrospray ionization source 100 can be configured to allow sheath gas from a sheath gas inlet line 120 to flow through a container 110, which can be filled with an organic solvent and additional chemical components, and into a desolvation gas outlet line 130.
[0187] In some exemplary embodiments, the electrospray ionization source 100 can provide a solvent flow rate of greater than about 5 μL / min to the electrospray. In one aspect, the electrospray ionization source 100 can provide a solvent flow rate of greater than about 5 μL / min, greater than about 6 μL / min, greater than about 7 μL / min, greater than about 8 μL / min, greater than about 9 μL / min, greater than about 10 μL / min, greater than about 11 μL / min, greater than about 12 μL / min, greater than about 13 μL / min, greater than about 14 μL / min, greater than about 15 μL / min, greater than about 16 μL / min, greater than about 17 μL / min, greater than about 18 μL / min, greater than about 20 μL / min, greater than about 21 μL / min, greater than about 22 μL / min, greater than about 23 μL / min, greater than about 24 μL / min, greater than about 25 μL / min, greater than about 26 μL / min, greater than about 27 μL / min, greater than about 28 μL / min, greater than about 29 μL / min, greater than about 30 μL / min, greater than about 31 μL / min, greater than about 32 μL / min, greater than about 33 μL / min, greater than about 34 μL / min, greater than about 35 μL / min, greater than about 36 μL / min, greater than about 37 μL / min, greater than about 38 μL / min, greater than about 39 μL / min, greater than about 40 μL / min, greater than about 41 μL / min, greater than about 42 μL / min, greater than about 43 μL / min, greater than about 44 μL / min, greater than about 45 μL / min, greater than about 46 μL / min, greater than about greater than about 17 μL / min, greater than about 18 μL / min, greater than about 19 μL / min, greater than about 20 μL / min, greater than about 25 μL / min, greater than about 30 μL / min, greater than about 35 μL / min, greater than about 40 μL / min, greater than about 45 μL / min, greater than about 50 μL / min, greater than about 55 μL / min, greater than about 60 μL / min, greater than about 65 μL / min, greater than about 70 μL / min, greater than about 75 μL / min , greater than about 80 μL / min, greater than about 85 μL / min, greater than about 90 μL / min, greater than about 95 μL / min, greater than about 100 μL / min, greater than about 110 μL / min, greater than about 120 μL / min, greater than about 130 μL / min, greater than about 140 μL / min, greater than about 150 μL / min, greater than about 160 μL / min, greater than about 170 μL / min, greater than about 180 μL / min, greater than about 190 μL / min Solvent flow rates of greater than about 200 μL / min, greater than about 225 μL / min, greater than about 250 μL / min, greater than about 275 μL / min, greater than about 300 μL / min, greater than about 325 μL / min, greater than about 350 μL / min, greater than about 375 μL / min, greater than about 700 μL / min, greater than about 425 μL / min, greater than about 450 μL / min, or greater than about 500 μL / min may be provided.
[0188] In some exemplary embodiments, the mass spectrometer 30 may be capable of identifying constituent components of a protein in order to characterize the protein.
[0189] In some exemplary embodiments, the mass spectrometer 30 can be a tandem mass spectrometer.
[0190] In some exemplary embodiments, the mass spectrometer 30 can be a temporal tandem mass spectrometer.
[0191] In some exemplary embodiments, the mass spectrometer 30 can be a spatial tandem mass spectrometer.
[0192] In some exemplary embodiments, the mass spectrometer 30 can be of a hybrid type, where a temporal tandem analyzer can be spatially coupled or coupled with a spatial tandem analyzer.
[0193] In some exemplary embodiments, the mass spectrometer 30 can be a quadrupole-orbitrap hybrid mass spectrometer. The quadrupole-orbitrap hybrid mass spectrometer can be a Q Exactive™ Focus Hybrid Quadrupole-Orbitrap™ mass spectrometer, a Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™ mass spectrometer, a Q Exactive™ BioPharma Platform, a Q Exactive™ UHMR Hybrid Quadrupole-Orbitrap™ mass spectrometer, a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ mass spectrometer, a Q Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ mass spectrometer, and a Q Exactive™ Hybrid Quadrupole-Orbitrap™ mass spectrometer.
[0194] In some exemplary embodiments, the mass spectrometer 30 can be a QIT-FTICR.
[0195] In some exemplary embodiments, the mass spectrometer 30 can be a Qq-FTICR.
[0196] In some exemplary embodiments, the method of characterizing a protein in a sample can include detecting or quantifying the protein in the sample.
[0197] In an exemplary embodiment, the protein can include an antibody, a bispecific antibody, an antibody fragment, or a multispecific antibody.
[0198] In some exemplary embodiments, the protein can be a therapeutic antibody.
[0199] In some exemplary embodiments, the protein can be an immunoglobulin protein.
[0200] In an exemplary embodiment, the immunoglobulin protein can be IgG1.
[0201] In an exemplary embodiment, the immunoglobulin protein can be IgG4.
[0202] In some exemplary embodiments, the protein can be a bispecific antibody.
[0203] In some exemplary embodiments, the protein can be an antibody fragment formed upon digestion of an antibody.
[0204] In an exemplary embodiment, the protein can be a protein variant.
[0205] In an exemplary embodiment, the protein can be a post-translationally modified protein.
[0206] In an exemplary embodiment, a post-translationally modified protein can be formed by cleavage, N-terminal extension, proteolysis, N-terminal acylation, biotinylation, C-terminal amidation, oxidation, glycosylation, iodination, covalent attachment of a prosthetic group, acetylation, alkylation, methylation, adenylation, ADP-ribosylation, covalent cross-linking within or between polypeptide chains, sulfonation, prenylation, vitamin C-dependent modification, vitamin K-dependent modification, glutamylation, glycylation, glycosylation, deglycosylation, isoprenylation, lipoylation, phosphopantetheinylation, phosphorylation, sulfation, citrullination, deamidation, formation of disulfide bridges, proteolytic cleavage, ISGylation, SUMOylation, or ubiquitination (covalent attachment of protein ubiquitin).
[0207] In an exemplary embodiment, a post-translationally modified protein can be formed when a protein is oxidized.
[0208] In another exemplary embodiment, the degradation products can include post-translational modifications of a therapeutic protein.
[0209] In another exemplary embodiment, the protein can be a protein degradation product.
[0210] In yet another exemplary embodiment, the protein can be an impurity found in a biopharmaceutical product.
[0211] In another exemplary embodiment, the protein can be an impurity found during the manufacture of a biologic.
[0212] In some exemplary embodiments, the protein can be a protein with a pI in the range of about 4.5 to about 9.0. In one aspect, the protein can be a protein with a pI of about 4.5, about 5.0, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1 about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1 about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1 about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, about 8.8, about 8.9, or about 9.0.
[0213] In some exemplary embodiments, the protein can be a product-derived impurity. The product-derived impurity can be a molecular variant, a precursor, a degradation product, a fragmented protein, a digestion product, an aggregate, a post-translational modification, or a combination thereof.
[0214] In some specific exemplary embodiments, the protein can be a process-derived impurity. Process-derived impurities can include impurities derived from the manufacturing process, such as nucleic acids and host cell proteins, antibiotics, serum, other media components, enzymes, chemical and biochemical treatment reagents, inorganic salts, solvents, carriers, ligands, and other leakage products used in the manufacturing process.
[0215] In some specific exemplary embodiments, the protein can be an impurity. In an exemplary embodiment, the number of impurities in the sample can be at least two.
[0216] In some exemplary embodiments, the mobile phase used to elute the protein can be a mass spectrometer compatible mobile phase.
[0217] In some exemplary embodiments, the mobile phase used in the liquid chromatography device can include water, acetonitrile, trifluoroacetic acid, formic acid, or combinations thereof.
[0218] In some exemplary embodiments, the mobile phase can have a flow rate of about 0.1 ml / min to about 0.4 ml / min in the liquid chromatography device. In one aspect, the flow rate of the mobile phase in the liquid chromatography device can be about 0.1 ml / min, about 0.15 ml / min, about 0.20 ml / min, about 0.25 ml / min, about 0.30 ml / min, about 0.35 ml / min, or about 0.4 ml / min.
[0219] It is understood that the system is not limited to the proteins, impurities, mobile phases, mass spectrometers, organic solvents, acids, bases, or chromatography columns described above.
[0220] The sequential numbering of method steps given numbers and / or letters herein does not limit the method, or any of its embodiments, to the particular order presented.
[0221] Throughout this specification, various publications are referenced, including patents, patent applications, patent application publications, accession numbers, technical papers, and journal articles. Each of these references mentioned is incorporated herein in its entirety for all purposes.
[0222] The present disclosure will be more fully understood by reference to the following examples, which are provided to further illustrate the present disclosure and are for illustrative purposes and should not be construed as limiting the scope of the disclosure. EXAMPLES
[0223] Materials. Deionized water was obtained by a Milli-Q Integral water purification system (Millipore Sigma, Burlington, MA) equipped with a MilliPak Express 20 filter. NIST monoclonal antibody standard 8671 (NISTmAb, a humanized IgG1κ monoclonal antibody) was purchased from the National Institute of Standards and Technology (Gaithersburg, MD). Rapid peptide N-glycosidase F (Rapid PNGase F) with 5× Rapid PNGase F buffer was purchased from New England Biolabs Inc. (Ipswich, MA). TCEP-HCl (tris(2-carboxyethyl)phosphine hydrochloride), Tris-HCl pH 7.5 (UltraPure), trifluoroacetic acid (LC-MS grade), formic acid (LC-MS grade) and acetonitrile (Optima LC / MS grade) were purchased from Thermo Fisher Scientific (Waltham, MA), trypsin (sequencing grade) was purchased from Promega (Madison, MI). Iodoacetamide, propionic acid and acetic acid were purchased from Sigma Aldrich, Co. (St. Louis, MO). 2-Propanol (HPLC grade) was purchased from VWR International, LLC (Radnow, PA).
[0224] Safety considerations. In the desolvation gas reforming experiments, the sheath gas was set at 15 arbitrary units. It may be possible to set it higher, but the pressure inside the bottle should be measured to ensure that the pressure rating of the bottle is never exceeded. A pressure-resistant bottle (e.g. Duran pressure plus bottle, pressure rating: +1.5 bar) was highly recommended for this application. A secondary container was also required for this setup to prevent possible acid or base leakage.
[0225] Example 1 1.1 Sample preparation NISTmAb stock samples (100 μg) were diluted in 5 mM acetic acid and reduced with 5 mM TCEP-HCl for 10 min at 80° C. After adjusting the pH to 7.5 with 1 M Tris-HCl (pH 7.5), 10 mM iodoacetamide and 5 μg trypsin (E / S ratio 1:20) were added and the samples were incubated for 3 h at 37° C. Finally, the solution was acidified with 1% TFA to stop the digestion.
[0226] 1.2 LC-MS analysis For peptide mapping analysis of NISTmAb, a portion of the digest (2 μg) was separated using an ACQUITY UPLC Peptide BEH C18 column (130 Å, 1.7 μm, 2.1 mm × 150 mm) (Waters, Milford, MA) for online LC-MS / MS analysis on a Q-Exactive mass spectrometer. For the separation, mobile phase A was 0.1% FA (v / v) in water and mobile phase B was 0.1% FA in acetonitrile (ACN). Detailed LC gradient and MS parameters are listed in Tables 1 and 2, respectively.
[0227] Table 1. LC gradients for peptide mapping analysis. TIFF2024166268000002.tif76164
[0228] Table 2. MS parameters for peptide mapping analysis. TIFF2024166268000003.tif56164 a : The sheath gas setting was lowered to 15 arbitrary units to reduce pressure in the solvent bottle.
[0229] 1.3 Results FIG. 3 shows the base peak chromatogram (BPC) obtained from LC-MS analysis of a tryptic digest of NISTmAb on a BEH C18 column using FA as the mobile phase.
[0230] Example 2 2.1 Sample preparation Sample preparation was carried out as described in 1.1.
[0231] 2.2 LC-MS analysis For peptide mapping analysis of NISTmAb, a portion of the digest (2 μg) was separated using an ACQUITY UPLC Peptide BEH C18 column (130 Å, 1.7 μm, 2.1 mm×150 mm) (Waters, Milford, MA) for online LC-MS / MS analysis on a Q-Exactive mass spectrometer. For the separation, mobile phase A was 0.05% TFA (v / v) in water and mobile phase B was 0.045% TFA (v / v) in ACN. The LC gradient and MS parameters implemented are listed in Tables 1 and 2, respectively.
[0232] 2.3 Results Figure 4 shows the base peak chromatograms (BPCs) obtained from the LC-MS analysis of the tryptic digest of NISTmAb on a BEH C18 column with TFA as the mobile phase. Comparing the BPCs in Figures 3 and 4, it is clear that the use of either FA or TFA as the mobile phase modifier resulted in significant differences in the separation and retention of tryptic peptides on the C18 column. In general, TFA outperforms FA in terms of chromatographic performance, exhibiting better retention of hydrophilic peptides, better peak shape, and overall higher peak capacity. For example, the small tryptic peptide EYK (P1, Figure 4) is not retained on a C18 column when FA is used, whereas it is retained on the same column when TFA is applied. This feature may improve the sequence coverage of protein biologics in peptide mapping analysis. On the other hand, the TFA-based analysis exhibited a significant loss of MS sensitivity compared to the FA-based analysis.
[0233] Example 3 3.1 Sample preparation Sample preparation was carried out as described in 1.1.
[0234] 3.2 LC-MS analysis LS-MS analysis was carried out as described in 2.2.
[0235] 3.3 Reforming of desolvation gas The sheath gas stream from the Q-Exactive mass spectrometer was transferred to a Duran pressure plus bottle (SCHOTT North America, Inc., Elmsford, NY) through a Canary-Safe cap (Analytical Sales and Services, Inc., Flanders, NJ) using 1 / 8" TEFLON® tubing (Figure 1). The tubing exiting the bottle was then reconnected to the HESI-II probe of a Thermo Scientific Ion Max ion source. For peptide mapping analysis, 150 mL of propionic acid (PA) and 50 mL of isopropanol (IPA) were mixed and transferred to the bottle. The bottle containing PA and IPA was then placed into a polyethylene secondary container (BEL-ART Acid / Solvent Bottle Carrier, Wayne, NJ) with a 16 mm opening at the top for the insertion of tubing. To circumvent modification, the sheath gas tubing was connected directly to the HESI-II probe without passing through this device.
[0236] 3.4 Results Base peak chromatograms (BPCs) from LC-MS analysis of a tryptic digest of NISTmAb using trifluoroacetic acid as the mobile phase on a BEH C18 column with desolvation modification enabled are shown in Figure 5. Comparing the BPCs in Figure 5 (mobile phase containing TFA, desolvation gas modification enabled) with Figure 3 (mobile phase containing TFA, desolvation gas modification disabled) and Figure 4 (mobile phase containing TFA, desolvation gas modification disabled), it is clear that modification of the desolvation gas with acid vapors from PA and IPA led to a significant increase in MS sensitivity for the TFA-based analysis.
[0237] As demonstrated by six representative tryptic peptides of different sizes and retention times (Table 3 below), a 4.9-5.8-fold increase in MS sensitivity was easily achieved with this approach, independent of peptide size and mobile phase composition. In addition, a slight increase in charge state was also consistently observed after desolvation gas reformulation. This feature may lead to improved spectral quality in tandem MS due to increased fragmentation efficiency of highly charged species, and subsequently more confident identification. Taken together, peptide mapping methods with significantly improved sensitivity can be easily achieved by reforming the desolvation gas with acid vapor using the developed device. The gained MS sensitivity will be of great value for characterizing low abundance attributes present in protein biologics, such as PTMs and sequence variants.
[0238] Table 3. Comparison of MS intensities and average charge states of six representative tryptic peptides from NISTmAb analyzed under three conditions. TIFF2024166268000004.tif90166
[0239] Example 4 4.1 Sample preparation Initial sample preparation was performed as described in 1.1, except that NISTmAb digestion was repeated on two consecutive days to assess whether the new approach could be applied to sequential analyses and whether the improved sensitivity could be maintained over a long period of time for peptide mapping analysis.
[0240] 4.2 LC-MS analysis LS-MS analysis was carried out as described in 2.2.
[0241] 4.3 Reforming of desolvation gas The reforming of the desolvation gas was carried out as described in 3.3.
[0242] 4.4 Results Again, by activating the desolvation gas reforming with acid vapor as described in 3.3, an improvement in MS sensitivity was immediately achieved compared to the control method (described in Example 3), which was maintained over at least 37 consecutive experiments (about 3800 min) tested (see FIG. 6). The consumption of the mixture of PA and IPA was estimated at 1 mL per hour for the applied experimental conditions. As a result, the developed approach is highly suitable for routine peptide mapping analysis of protein biopharmaceuticals, where the consecutive analysis of large sample sets may often be required.
[0243] Example 5 Examples 1-4 illustrate the results of using the desolvation gas approach for peptide mapping analysis. Experiments were performed using a weak base desolvation gas approach to evaluate whether the same approach could be utilized to improve intact mass analysis of protein biologics through charge reduction.
[0244] 5.1 Sample preparation 10 mM TCEP-HCl was added to the diluted NISTmAb solution (1 μg / μL) and the sample was incubated for 30 min at 50° C. To remove N-glycans present on the reagent protein X, the protein sample was first diluted to 0.25 μg / μL with 5× Rapid PNGase F buffer (containing a reducing agent) and then the solution was incubated for 10 min at 80° C. Rapid PNGase F was then added to the solution and the sample was incubated for 30 min at 50° C.
[0245] 5.2 RPLC analysis For intact mass analysis of reduced NISTmAb and reagent protein X, a portion of each sample (4 μg) was separated using a BioResolve RP mAb polyphenyl column (50 mm × 2.1 mm, 2.7 μm) (Waters, Milford, MA) for online LC-MS analysis on a Q-Exactive mass spectrometer. Detailed LC gradient and MS parameters are listed in Tables 4 and 5, respectively.
[0246] Table 4. LC gradients for intact mapping analysis. TIFF2024166268000005.tif61164
[0247] Table 5. MS parameters for intact mass analysis of reduced NISTmAb and reagent protein X. TIFF2024166268000006.tif56164 a : The sheath gas setting was lowered to 15 arbitrary units to reduce pressure in the solvent bottle. b :Scan range changed due to charge reduction.
[0248] 5.3 Reforming of desolvation gas The sheath gas stream from the Q-Exactive mass spectrometer was transferred to a Duran pressure plus bottle (SCHOTT North America, Inc., Elmsford, NY) using 1 / 8" TEFLON® tubing through a Canary-Safe cap (Analytical Sales and Services, Inc., Flanders, NJ) (see Figure 1). The tubing exiting the bottle was then reconnected to the HESI-II probe of a Thermo Scientific Ion Max ion source. For intact mass analysis, 1% triethylamine (TEA) (v / v) in 200 mL of acetonitrile was transferred to the bottle. The bottle containing the concentrated acid or base was then placed into a polyethylene secondary container (BEL-ART Acid / Solvent Bottle Carrier, Wayne, NJ) with a 16 mm opening at the top for the insertion of the tubing. To negate modification, the sheath gas tubing was connected directly to the HESI-II probe without passing through this device.
[0249] 5.4 Results To evaluate whether a similar improvement could be achieved by desolvation gas reformulation, reduced NISTmAb was used as a test article. Triethylamine (TEA) was diluted to 1% (v / v) with acetonitrile (ACN) and used to deliver base vapor in the desolvation gas. MS spectra of the reduced heavy chain of NISTmAb obtained with the control and desolvation gas reformulation methods after chromatographic separation on a reversed-phase (RP) polyphenol column are both shown in Figure 7 (control method) and Figure 8 (charge reduction method). After enabling reformulation, significant charge reduction was achieved on the NISTmAb heavy chain, from charge state +23 to +55 to charge state +14 to +28. Closer examination of charge state +39 from the control method revealed high levels of background noise. This was likely due to the decay of highly charged heavy chain species during MS analysis, such as neutral losses of water (-18 Da), ammonia (-17 Da) and carboxylic acid (-44 Da), as well as protein backbone fragmentation losses.
[0250] In contrast, the zoom in charge state +21 from the modified method exhibited a significantly improved signal-to-noise ratio, allowing the identification of several low-abundance glycoforms not detected by the control method. The deconvoluted mass spectrum (see FIG. 9) and mass analysis (Table 6) further demonstrated that the modified method can accurately identify glycoforms present at a low rate of only 0.3% on the heavy chain of NISTmAb. The improved spectral quality is not only due to significantly simplified spectra due to a sparser charge state envelope, but more importantly, is also the result of stabilized protein analytes. This is consistent with the established finding that the collision energy associated with a protein ion in MS analysis is proportional to its charge state. Specifically, lower charge states decay more slowly during analysis in the Orbitrap than the same analyte in a higher charge state. In particular, efforts to mitigate the severe disruption of highly charged heavy chain species from the control method were ineffective, even after the complete removal of source-induced dissociation (SID) energy. In contrast, the charge reduction method can easily tolerate high levels of SID energy (75 eV used in this experiment) without significant disruption or fragmentation of the heavy chains, which further improves the spectral quality due to more efficient desolvation and adduct removal. A similar improvement in spectral quality was achieved for the reduced light chain of NISTmAb (see FIG. 10). It is noteworthy that the application of charge reduction strategies to improve MS spectral quality is most useful for fully denatured and reduced proteins, since they are often highly charged (due to increased protein surface area (Kaltashov and Mohimen. Analytical chemistry 2005, 77, 5370-5379)) and are most susceptible to undesired fragmentation and disruption during ESI-MS analysis.
[0251] (Table 6) TIFF2024166268000007.tif79166
[0252] Example 6 In addition, the developed charge reduction method, achieved by modifying the desolvation gas with TEA, can also be utilized to address the high mass heterogeneity present in complex protein samples. These can include a variety of protein reagents that are critical to support various assays during the development of protein biopharmaceuticals. The use of intact mass analysis to confirm the identity of those protein reagents, whether they are obtained from commercial sources or produced in-house, is often necessary to support subsequent studies. Some protein reagents are highly heterogeneous in molecular weight due to extensive glycosylation, which can pose a significant challenge for routine intact mass methods. To demonstrate the utility of the developed charge reduction method, a complex reagent protein (protein X) with high mass heterogeneity was used as a test article.
[0253] 6.1 Sample preparation Prior to analysis, protein X was first treated with PNGase F under denaturing and reducing conditions to remove mass heterogeneity introduced by the presence of N-glycans. As shown in Figure 11, even after PNGase F treatment, protein X exhibited a highly convoluted MS spectrum that could not be deciphered by conventional intact mass methods. This was likely due to overlapping charge envelopes from various co-eluting masses of this molecule in the low m / z region.
[0254] 6.3 Reforming of desolvation gas Desolvation gas reforming was carried out as described in 5.3.
[0255] 6.4 Results In contrast to the results obtained in Example 6.1, after enabling the desolvation gas modification with TEA, the MS signal of the same sample immediately shifted to the higher m / z region and exhibited much better resolved charge states. The deconvoluted spectrum (see FIG. 12) then clearly revealed that the protein was heavily modified with O-glycans, with perhaps 10 different glycosylation sites and 4 different O-glycan types. Altogether, close to 35 different mass species from this protein were identified and assigned with high confidence. It is noteworthy that the dramatically improved spectral quality could also be attributed to more stabilized protein ions after charge reduction, since the polysaccharide portion of this molecule would be unstable under normal ESI-MS conditions.
[0256] Finally, the developed approach was also tested for several other LC-MS-based intact mass methods where the use of TFA is unavoidable to ensure chromatographic performance, to combat TFA ion suppression at the protein level using PA / IPA modified desolvation gas. For example, hyphenation of size-exclusion chromatography (SEC) to MS using a mobile phase containing acetonitrile, TFA and formic acid has been used for reduced mAb analysis (Liu et al. Journal of the American Society for Mass Spectrometry 2009, 20, 2258-2264). Hyphenation of hydrophilic interaction chromatography to MS using a TFA-containing mobile phase has been used to study low molecular weight impurities in mAb samples (Wang et al. Journal of pharmaceutical and biomedical analysis 2018, 154, 468-475). In both methods, significant improvements in MS sensitivity can be achieved for many mAb fragments (e.g. heavy chains, light chains and smaller fragments) using PA / IPA modified desolvation gas. However, the MS sensitivity of intact mAb (~150 kDa) was not improved as a result of this modification. This finding is consistent with previous studies that hypothesized that larger proteins may accommodate a larger number of TFA anions and not be able to effectively replace them with PA during the ESI process (Apffel et al. Journal of chromatography. A 1995, 712, 177-190).
[0257] Thus, desolvation gas modification using a simple device demonstrates an effective approach to improve both data quality from peptide mapping analysis and intact mass analysis. By using PA / IPA modified desolvation gas, TFA ion suppression from typical peptide mapping methods can be effectively alleviated, thus resulting in significantly improved MS sensitivity. The developed approach is particularly suitable for routine characterization of protein biotherapeutics, as it can be easily implemented without changing the LC method and allows for the sequential analysis of large sample sets. By using TEA modified desolvation gas, this new approach could also be utilized to improve intact mass analysis of proteins through charge reduction. The significant improvement in spectral quality not only allows the detection of trace mass entities that would otherwise be buried in noise, but also allows for mass measurement of highly heterogeneous proteins. Finally, as LC-MS techniques continue to play an increasing role in the characterization of protein biotherapeutics, the developed approach can contribute more deeply and broadly by serving as a low-cost and practical measure to improve analytical capabilities and better support drug development. [Explanation of symbols]
[0258] 100 Electrospray Ionization Source 110 Container 120 Sheath Gas Inlet Line 130 Desolvation gas outlet line 140 Electrospray Ionization Probe 150 Cap 160 Inlet Line Port 170 Outlet Line Port 180 Sheath Gas Inlet 190 Auxiliary Gas Inlet 200 Sheath Gas Source 210 Auxiliary Gas Source 220 Auxiliary Gas Inlet Line 230 Second container [Prior art documents] [Patent documents]
[0259] [Patent Document 1] U.S. Patent No. 8,586,713 [Patent Document 2] U.S. Patent No. 9,657,102 [Patent Document 3] U.S. Pat. No. 10,179,819 [Patent Document 4] US Patent Application Publication No. 2013 / 0045492 [Patent Document 5] US Patent Application Publication No. 2016 / 0024147 [Patent Document 6] US Patent Application Publication No. 2018 / 0112001 [Patent Document 7] US Patent Application Publication No. 2018 / 0104357 [Patent Document 8] US Patent Application Publication No. 2017 / 0174779 [Patent Document 9] US Patent Application Publication No. 2017 / 0174781 [Patent Document 10] US Patent Application Publication No. 2018 / 0134794 [Non-patent literature]
[0260] [Non-Patent Document 1] Journal of Pharmaceutical and Biomedical Analysis, Vol. 154, 2018, p.468-475 [Non-Patent Document 2] Journal of Hermatology & Oncology, 8:130; 2015, 838-847 [Non-Patent Document 3] Clinical Chemistry 49:7; 2003, p.1041-1044 [Non-Patent Document 4] PLoS ONE Volume 7, Issue 7, e40328, July 2012, p.1-10 [Non-Patent Document 5] Guidance for Industry, Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological / Biological Products, US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, August 1999 [Non-Patent Document 6] Journal of American Society for Mass Spectrometry, August 2009, 20, p.2258-2264 [Non-Patent Document 7] Drug Discovery Today, Volume 20, November 7, July 2015, p.838-847 [Non-Patent Document 8] Biotechnology and Genetic Engineering Reviews; Volume 28, 2012, p.147-175 [Non-Patent Document 9] Journal Chromatography A. 2005 July 1, 1080(1), p.68-75 [Non-Patent Document 10] Analytical and Bioanalytical Chemistry, 2018, 410:2111-2126 [Non-Patent Document 11] Journal of Chromatography A. 712,1995, p.177-190 [Non-Patent Document 12] Journal of Pharmaceutical and Biomedical Analysis 21, 2000, p.1099-1128 [Non-Patent Document 13] Chemical Communications, The Royal Society of Chemistry, 2015, 51, 14758-14760 [Non-Patent Document 14] Analytical Chemistry 2005, 77, 5370-5379 [Non-Patent Document 15] Journal of Proteome Research, 2013, 12, 1067-1077
[0261] Sequence information SEQUENCE LISTING <110> REGENERON PHARMACEUTICALS INCORPORATED <120> SYSTEM AND METHOD OF ANALYSIS OF A PROTEIN USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY <150> US 62 / 778,521 <151> 2018-12-12 <160> 6 <170> PatentIn version 3.5 <210> 1 <211> 3 <212> PRT <213> Homo sapiens <400> 1 Glu-Tyr-Lys 1 <210> 2 <211> 20 <212> PRT <213> Homo sapiens <400> 2 Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu 1 5 10 15 Gln Asp Ser Lys 20 <210> 3 <211> 17 <212> PRT <213> Homo sapiens <400> 3 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 1 5 10 15 Lys <210> 4 <211> 14 <212> PRT <213> Homo sapiens <400> 4 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 1 5 10 <210> 5 <211> 17 <212> PRT <213> Homo sapiens <400> 5 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 1 5 10 15 Lys <210> 6 <211> 63 <212> PRT <213> Homo sapiens <400> 6 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 1 5 10 15 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 20 25 30 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 35 40 45 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 50 55 60
Claims
1. a container having a cap with an inlet line port and an outlet line port, the container containing an organic solvent and an acid, the volume of the organic solvent being less than the volume of the acid; a sheath gas inlet line for providing sheath gas to the inlet line port; A modified desolvation gas outlet line whose outlet line port can be connected to the sheath gas inlet of an electrospray ionization probe; 1. An electrospray ionization source comprising:
2. 2. The electrospray ionization source of claim 1, wherein the organic solvent is selected from the group consisting of acetonitrile, propanol, isopropanol, and methanol.
3. 2. The electrospray ionization source of claim 1, wherein the acid is selected from the group consisting of acetic acid, propionic acid, and formic acid.
4. 10. The electrospray ionization source of claim 1, wherein the ratio of organic solvent to acid in the vessel is about 1:
3.
5. 2. The electrospray ionization source of claim 1, wherein the organic solvent is isopropanol.
6. 2. The electrospray ionization source of claim 1, wherein the acid is propionic acid.
7. 10. The electrospray ionization source of claim 1, wherein the electrospray ionization probe comprises an auxiliary gas inlet.
8. 8. The electrospray ionization source of claim 7, wherein an auxiliary gas is provided to the auxiliary gas inlet.
9. 10. The electrospray ionization source of claim 1, wherein the electrospray ionization probe comprises an electrospray emitter needle, a sheath gas flow line, and an auxiliary gas flow line.
10. 10. The electrospray ionization source of claim 9, wherein the electrospray ionization probe is configured to direct flow in the sheath gas flow tubing coaxially with respect to the electrospray emitter needle.
11. 10. The electrospray ionization source of claim 9, wherein the electrospray ionization probe is configured to direct flow in the auxiliary gas flow tubing coaxially with respect to the electrospray emitter needle.
12. 10. The electrospray ionization source of claim 1, wherein the sheath gas inlet line is partially inserted into the inlet line port.
13. 10. The electrospray ionization source of claim 1, wherein the modified desolvation gas outlet line is partially inserted into the outlet line port.
14. 10. The electrospray ionization source of claim 1, wherein the sheath gas flows from a sheath gas inlet line, through a vessel containing the organic solvent, and into a desolvation gas outlet line.
15. 10. The electrospray ionization source of claim 1, wherein the vessel is surrounded by a second vessel.
16. 13. The electrospray ionization source of claim 1, capable of being connected to a liquid chromatography system.
17. a container having a cap with an inlet line port and an outlet line port, the container containing an organic solvent and an acid, the volume of the organic solvent being less than the volume of the acid; a sheath gas inlet line for providing sheath gas to the inlet line port; A modified desolvation gas outlet line whose outlet line port can be connected to the sheath gas inlet of an electrospray ionization probe; providing a sample to an inlet of an electrospray ionization source comprising: generating ions of protein constituents in the sample at the outlet of an electrospray ionization source; and Characterizing the protein by analyzing the ions using a mass spectrometer to identify the protein components A method for characterizing proteins in a sample, comprising:
18. 20. The method of claim 17, wherein the electrospray ionization source is connected to a liquid chromatography system.
19. 20. The method of claim 17, wherein the electrospray ionization probe is in a positive polarity mode.
20. 20. The method of claim 17, wherein the electrospray ionization probe is in a negative polarity mode.
21. 20. The method of claim 17, wherein the step of characterizing the protein comprises performing intact mass analysis.
22. 20. The method of claim 17, wherein the step of characterizing the protein comprises performing a peptide mapping analysis.
23. 18. The method of claim 17, wherein the protein is an antibody.
24. 20. The method of claim 17, wherein the electrospray ionization source provides a solvent flow rate for the electrospray of greater than about 5 μL / min.
25. 1. A liquid chromatography device configured to direct a sample stream to an electrospray ionization source, comprising: An electrospray ionization source, a container having a cap with an inlet line port and an outlet line port, the container containing an organic solvent and an acid, the volume of the organic solvent being less than the volume of the acid; a sheath gas inlet line for providing a sheath gas to the inlet line port; A modified desolvation gas outlet line whose outlet line port can be connected to the sheath gas inlet of an electrospray ionization probe; and an electrospray ionization source configured to charge and desolvate the sample to form ions of constituents of the sample; Liquid chromatography equipment, A mass analyzer configured to receive ions and characterize the mass-to-charge ratio of the ions. A liquid chromatography mass spectrometry system comprising:
Citation Information
Patent Citations
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
US10179819B2
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130045492A1
Purification Platform for Bispecific Antibodies
US20160024147A1
Combination of Anti-PD-1 Antibodies and Anti-CD20 / Anti-CD3 Antibodies to Treat Cancer
US20170174779A1
Bispecific Anti-CD20 / Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
US20170174781A1
